Ann Clin Microbiol.  2022 Sep;25(3):79-85. 10.5145/ACM.2022.25.3.2.

On-field evaluation of exdia COVID-19 antigen point-of-care testing in the emergency department during the COVID-19 pandemic

• Yoo IY
• Lee GD
• Chae H
• Youn CS
• Oh EJ
• Park YJ

• KMID: 2533951
• DOI: http://doi.org/10.5145/ACM.2022.25.3.2

Abstract

Background
We evaluated the diagnostic performance of the Exdia COVID-19 antigen test (Exdia Ag; Precision Biosensor Inc., Korea) as a point-of-care (POC) test performed in the emergency department (ED) for the rapid detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in comparison with the performance of the Real-Q 2019-nCoV Detection KIT (Real-Q; BioSewoom, Korea).
Methods
Exdia Ag and Real-Q assays were performed simultaneously for all patients who were admitted to the ED with or without COVID-19 symptoms between December 2021 and March 2022.
Results
Among the 2,523 samples analyzed by Real-Q assay, 149 samples (5.9%) showed positive results, and 2,374 samples showed negative results. The overall sensitivity and specificity of the Exdia Ag assay were 77.2% (95% confidence interval [CI], 69.6 – 83.7) and 99.8% (95% CI, 99.6 – 99.9), respectively. The positive and negative predictive values were 96.6% (95% CI, 91.5 – 98.7) and 98.6% (95% CI, 98.1 – 98.9), respectively. The cycle threshold value for 115 concordant Exdia Ag-positive/Real-Q-positive samples was significantly lower than that for 34 discordant Exdia Ag-negative/Real-Q-positive samples (P < 0.0001)
Conclusion
The Exdia Ag assay showed good diagnostic performance when the disease prevalence was high and may be useful for POC testing when the rapid detection of SARSCoV-2 is required for the isolation of patients in the ED.

Keyword

Antigens; Emergency department; Point-of-care testing; SARS-CoV-2

Reference

1. Bernard K. The genus Corynebacterium and other medically relevant coryneform-like bacteria. J Clin Microbiol 2012;50:3152-8. .

2. Patricia MT. Bailey and Scott’s Diagnostic Microbiology. 14th ed. Elsevier, 2017:137-58. .

3. Scholle D. A spontaneous joint infection with Corynebacterium striatum. J Clin Microbiol 2007;45:656-8. .

4. Carroll KC, Pfaller MA, et al. Manual of Clinical Microbiology. 12th ed. American Society for Microbiology; 2019: 488-524. .

5. Hong HL, Koh HI, Lee AJ. Native valve endocarditis due to Corynebacterium striatum confirmed by 16S ribosomal RNA sequencing: a case report and literature review. Infect Chemother 2016;48:239-45. .

6. Renom F, Gomila F, Garau M, Gallegos MD, Guerrero D, Lalucat J, et al. Respiratory infection by Corynebacterium striatum: epidemiological and clinical determinants. New Microbes New Infect 2014;2:106-14 .

7. Cone LA, Curry N, Wuestoff MA, O’Connell SJ, Feller JF. Septic synovitis and arthritis due to Corynebacterium striatum following an accidental scalpel injury. Clin Infect Dis 1998;27:1532–3. .

8. Weiss K, Labbé AC, Laverdière M. Corynebacterium striatum meningitis: case report and review of an increasingly important Corynebacterium species. Clin Infect Dis 1996;23:1246–8. .

9. Song SA, Shin JH. Microbiological characteristics of Corynebacterium striatum, an emerging pathogen. Hanyang Med Rev 2018;38:93-8. .

10. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; CLSI M45–ED3. Wayne; PA:2015. .

11. Hahn WO, Werth BJ, Butler-Wu SM, Rakita RM. Multidrug-resistant Corynebacterium striatum associated with increased use of parenteral antimicrobial drugs. Emerg Infect Dis 2016;22:1908-14. .

12. Otsuka Y, Ohkusu K, Kawamura Y, Baba S, Ezki T, Kimura S. Emergence of multidrugresistant Corynebacterium striatum as a nosocomial pathogen in long-term hospitalized patients with underlying diseases. Diagn Microbiol Infect Dis 2006;54:109-14. .